Nordson Corporation recently announced strong Q4 FY23 and FY23 results, with sales growth and improved gross margin. The company is expecting FY24 sales to be around 6.5% higher than FY23 sales, wi...

Nordson's (NDSN) fourth-quarter fiscal 2023 revenues increase 5.2% due to strong momentum in the Industrial Precision Solutions segment.

While the top- and bottom-line numbers for Nordson (NDSN) give a sense of how the business performed in the quarter ended October 2023, it could be worth looking at how some of its key metrics comp...

Beyond analysts' top -and-bottom-line estimates for Nordson (NDSN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quar...

Softness in the product assembly and nonwoven product lines has been taking a toll on Nordson's (NDSN) operations. The escalating cost of sales adds to the company's woes.

Investments in automation and electronic product innovation, and accretive acquisitions augur well for Nordson (NDSN). The company's measures to reward its shareholders are encouraging.

Nordson's (NDSN) acquisition of ARAG expands its core dispense capabilities and helps the company foray into the precision agriculture end market.

Nordson's (NDSN) third-quarter fiscal 2023 results reflect a year-over-year decline in the top line due to ongoing pressure in electronics and biopharma end markets. The company narrows its 2023 ou...

Nordson (NDSN) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.49 per share a year ago.

Although the revenue and EPS for Nordson (NDSN) give a sense of how its business performed in the quarter ended July 2023, it might be worth considering how some key metrics compare with Wall Stree...

Nordson Corp. shares NDSN, -0.41% fell nearly 7% in the aftermarket Monday after the maker of adhesives and other industrial products reported fiscal third-quarter revenue that missed estimates, mo...

Nordson's (NDSN) Q3 earnings are likely to have been hurt by weakness in the electronics end market and medical fluid components product lines, partly offset by benefits from the CyberOptics buyout.